CN114746096A - 使用阿伐替尼治疗嗜酸性粒细胞紊乱 - Google Patents
使用阿伐替尼治疗嗜酸性粒细胞紊乱 Download PDFInfo
- Publication number
- CN114746096A CN114746096A CN202080081643.7A CN202080081643A CN114746096A CN 114746096 A CN114746096 A CN 114746096A CN 202080081643 A CN202080081643 A CN 202080081643A CN 114746096 A CN114746096 A CN 114746096A
- Authority
- CN
- China
- Prior art keywords
- eosinophilic
- compound
- pharmaceutically acceptable
- eosinophils
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910931P | 2019-10-04 | 2019-10-04 | |
| US62/910,931 | 2019-10-04 | ||
| PCT/US2020/054221 WO2021067917A1 (en) | 2019-10-04 | 2020-10-05 | Treatment of eosinophilic disorders with avapritinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114746096A true CN114746096A (zh) | 2022-07-12 |
Family
ID=73030210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080081643.7A Pending CN114746096A (zh) | 2019-10-04 | 2020-10-05 | 使用阿伐替尼治疗嗜酸性粒细胞紊乱 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240075041A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4041244B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022551105A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114746096A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202126306A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021067917A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110003217A (zh) * | 2013-10-17 | 2019-07-12 | 蓝图药品公司 | 可用于治疗与kit相关的病症的组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2593319T3 (es) * | 2005-05-02 | 2016-12-07 | Novartis Ag | Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico |
| JP2009515978A (ja) * | 2005-11-14 | 2009-04-16 | バイエル ヘルスケア エルエルシー | Kit阻害剤に対する獲得耐性を伴う癌の治療 |
| ES2429107T3 (es) * | 2007-01-19 | 2013-11-13 | Bayer Healthcare Llc | Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT |
| ES2573831T3 (es) * | 2011-07-27 | 2016-06-10 | Ab Science | Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit) |
| EP2768480A1 (en) * | 2011-10-21 | 2014-08-27 | Rigel Pharmaceuticals, Inc. | Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine |
| KR101652229B1 (ko) * | 2012-06-07 | 2016-08-30 | 데시페라 파마슈티칼스, 엘엘씨. | 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물 |
| CN109970745B (zh) * | 2018-04-16 | 2020-12-08 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
-
2020
- 2020-10-05 CN CN202080081643.7A patent/CN114746096A/zh active Pending
- 2020-10-05 WO PCT/US2020/054221 patent/WO2021067917A1/en not_active Ceased
- 2020-10-05 TW TW109134501A patent/TW202126306A/zh unknown
- 2020-10-05 EP EP20797912.1A patent/EP4041244B1/en active Active
- 2020-10-05 JP JP2022520638A patent/JP2022551105A/ja active Pending
- 2020-10-05 US US17/766,200 patent/US20240075041A1/en active Pending
-
2025
- 2025-08-15 JP JP2025135336A patent/JP2025169361A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110003217A (zh) * | 2013-10-17 | 2019-07-12 | 蓝图药品公司 | 可用于治疗与kit相关的病症的组合物 |
Non-Patent Citations (1)
| Title |
|---|
| ANNA KOVALSZKI等: "Eosinophilia in Mast Cell Disease", IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, vol. 34, no. 2, pages 357 - 364 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022551105A (ja) | 2022-12-07 |
| EP4041244B1 (en) | 2026-07-15 |
| EP4041244A1 (en) | 2022-08-17 |
| JP2025169361A (ja) | 2025-11-12 |
| TW202126306A (zh) | 2021-07-16 |
| WO2021067917A1 (en) | 2021-04-08 |
| US20240075041A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190269671A1 (en) | Method for treating tumour, pharmaceutical composition and medicinal kit | |
| EP4385571A2 (en) | Uses of a lysyl oxidase-like 2 inhibitor related applications | |
| JP2015511632A (ja) | メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与 | |
| US20250017934A1 (en) | New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases | |
| US20170231975A1 (en) | Kinase Inhibitors | |
| US20230181590A1 (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
| JP2023058635A (ja) | 過活動膀胱の治療のためのビベグロンの投薬 | |
| US20240000789A1 (en) | Therapeutic combinations comprising a craf inhibitor | |
| JP2020522560A (ja) | 過活動膀胱を治療するためのビベグロンの使用 | |
| JP2025169361A (ja) | アバプリチニブでの好酸球性障害の治療 | |
| CN115038447A (zh) | 用于治疗癌症的组合疗法 | |
| US20190125751A1 (en) | Anticancer combination therapy | |
| TW202045180A (zh) | 治療纖維化之方法 | |
| CN114945371A (zh) | 肥大细胞疾病和嗜酸性粒细胞疾病的治疗 | |
| WO2010110428A1 (ja) | 掻痒の予防及び/または治療剤 | |
| CN112533600A (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
| TWI668005B (zh) | 逼尿肌過度活動伴收縮力降低之改善劑 | |
| CN106061505A (zh) | 用于治疗癌症的含pi3k抑制剂的药物组合 | |
| TW202308631A (zh) | 用於治療mpnst之化合物和組成物 | |
| KR20230061527A (ko) | 염증성 장 질환을 치료하는 방법 | |
| JP2026516050A (ja) | 多発性硬化症を治療するためのbtk阻害剤 | |
| KR20250145693A (ko) | 미토겐 활성화 단백질 키나제(mapk) 경로 변경을 이용한 고형 종양의 치료 방법 | |
| HK40086978A (en) | Therapeutic combinations comprising a craf inhibitor | |
| JP2022547311A (ja) | 骨髄線維症の治療のためのmdm2阻害剤の使用 | |
| WO2024148307A1 (en) | Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220712 |
|
| RJ01 | Rejection of invention patent application after publication |